{
  "model": "gpt-5.2",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e08fc00d88194a2fd3d1c5d9c5961\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"TASK.md\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_y9dMfTUnDZBpL3DdXiVuo6vB\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.",
            "callId": "call_y9dMfTUnDZBpL3DdXiVuo6vB"
          }
        ],
        "usage": {
          "promptTokens": 487,
          "cachedTokens": 0,
          "responseTokens": 30,
          "thinkingTokens": 14,
          "totalTokens": 531
        },
        "costUsd": 0.00146825
      },
      {
        "step": 2,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e08fef4b08194908b458b417c5b1c\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"schemas\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_C72HgwrjLayT6sR1O3KM3BtD\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_C72HgwrjLayT6sR1O3KM3BtD"
          }
        ],
        "usage": {
          "promptTokens": 938,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 14,
          "totalTokens": 996
        },
        "costUsd": 0.0024535
      },
      {
        "step": 3,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e09015f3c8194b8529afc081d2dcc\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/study_overview.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_qKz4h9JYMdHxYfjU1s2kVKJC\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e09015f4c81949dcd56aa047ee251\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/quantitative_findings.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_5VdScWfX7AHnBnP0JOl0fylh\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e09015f548194b5648482aa9bd4d2\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/claim_audit.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_dAmuOEDLZforwyJOZg8qaVX0\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e09015f5c8194b4d4042560ed0f1f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/public_summary.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_NzUyY3EhN4Vx4cCnOWAijAHY\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_qKz4h9JYMdHxYfjU1s2kVKJC"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_5VdScWfX7AHnBnP0JOl0fylh"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_dAmuOEDLZforwyJOZg8qaVX0"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_NzUyY3EhN4Vx4cCnOWAijAHY"
          }
        ],
        "usage": {
          "promptTokens": 1030,
          "cachedTokens": 0,
          "responseTokens": 135,
          "thinkingTokens": 0,
          "totalTokens": 1165
        },
        "costUsd": 0.0036925
      },
      {
        "step": 4,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e09032ed48194b865b64f9ec325e7\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"input/report.md\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_DidZb2UbloXkT40GEvxKdSPV\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_DidZb2UbloXkT40GEvxKdSPV"
          }
        ],
        "usage": {
          "promptTokens": 4122,
          "cachedTokens": 1024,
          "responseTokens": 31,
          "thinkingTokens": 16,
          "totalTokens": 4169
        },
        "costUsd": 0.0062587
      },
      {
        "step": 5,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e09205ab481948512edc68518c099\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"output\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_RJWToqDQNsUfp1WYIEwlFD1p\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_RJWToqDQNsUfp1WYIEwlFD1p"
          }
        ],
        "usage": {
          "promptTokens": 5244,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 1554,
          "totalTokens": 6842
        },
        "costUsd": 0.031549
      },
      {
        "step": 6,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e095a082881948639a3e8498b6593\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"paper\\\\\\\": {\\\\n    \\\\\\\"title\\\\\\\": \\\\\\\"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\\\\\\\",\\\\n    \\\\\\\"doi\\\\\\\": \\\\\\\"10.1038/s41586-025-09006-8\\\\\\\",\\\\n    \\\\\\\"publication_year\\\\\\\": 2025,\\\\n    \\\\\\\"domain\\\\\\\": \\\\\\\"oncology-immunology\\\\\\\",\\\\n    \\\\\\\"study_type\\\\\\\": \\\\\\\"preclinical+retrospective\\\\\\\"\\\\n  },\\\\n  \\\\\\\"core_question\\\\\\\": \\\\\\\"Can intratumoral delivery of an mRNA vaccine induce an interferon-rich inflammatory state that broadens antigen presentation and thereby sensitizes tumours to anti-PD-L1 immune checkpoint blockade, with supportive evidence in mice and a retrospective human cohort?\\\\\\\",\\\\n  \\\\\\\"datasets_or_cohorts\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-efficacy-combo\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse efficacy cohort (combination therapy)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"78 tumor-bearing mice pooled across repeat experiments\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Preclinical pooled mouse experiments testing intratumoral mRNA vaccine in combination with anti-PD-L1, focused on tumour control and immune changes under combination treatment.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-controls\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse control cohort (vaccine only, ICI only, and vehicle)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"84 tumor-bearing mice pooled across matched controls\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Matched mouse controls spanning vaccine-only, ICI-only, and vehicle arms used to benchmark whether sensitization requires the combination and to assess null/conditional responses.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-metastatic-retrospective\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human retrospective metastatic cohort\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"130 metastatic patients total\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Retrospective translational cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status for a survival comparison.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-vaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human vaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"43 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used as the exposed group in the survival comparison under ICI treatment.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-unvaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human unvaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"87 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for outcomes under ICI treatment.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"major_limitations\\\\\\\": [\\\\n    \\\\\\\"Human analysis was retrospective and non-randomized, so residual confounding is likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients.\\\\\\\",\\\\n    \\\\\\\"Tumour-type mix and treatment-history heterogeneity limits causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not map one-to-one to all human tumours.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic readouts were strongest in specific models rather than uniform across settings.\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_Kjz3v18ZDjTEf7bFOWETAeW5\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e095a0838819494aa0d70690d43a2\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"findings\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q01\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"62.3%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"37.3% comparator\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination was associated with broader antigen display in the immunopeptidome.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L28\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q02\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"40.6%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"20.6% comparator\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L29\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q03\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value under ICI\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"p=0.01\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"Vaccinated subgroup vs unvaccinated subgroup in a retrospective metastatic ICI-treated cohort\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"In the retrospective cohort, prior SARS-CoV-2 mRNA vaccination status correlated with improved survival during ICI treatment.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L30\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q04\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Type I interferon response score (normalized units)\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"3.1\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0 baseline\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"mRNA vaccination in tumours produced a marked induction of a type I interferon response signature.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L31\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q05\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"PD-L1 expression fold-change in tumor tissue\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"2.4x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x baseline\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"After mRNA vaccination, PD-L1 pathway activity increased, potentially increasing targetability for anti-PD-L1 therapy.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L32\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q06\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Intratumoral CD8+ T-cell density fold-change\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"1.8x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x baseline\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Combination therapy was associated with increased CD8+ T-cell infiltration into tumours.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L33\\\\\\\"]\\\\n    }\\\\n  ],\\\\n  \\\\\\\"controls_or_null_results\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L36\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"ICI-only treatment had limited activity in low-immunogenic baseline settings.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L37\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_ZVcewpaom60Eg2BGx1wsx7Vt\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e095a08448194a2583e516f0cc69a\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"claims\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C01\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination induces a type I interferon response in tumours.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L31\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"This report summarizes mechanistic induction primarily from tumour measurements and proposed chain; strength may vary by model system.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C02\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination broadens antigen presentation, including expansion of the MHC-I peptidome.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L28\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L29\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L44\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"These quantitative peptidome fractions are reported as preclinical readouts and may not directly translate to clinical tumour antigen presentation breadth.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C03\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The combined strategy (intratumoral mRNA vaccination plus anti-PD-L1) improves tumour control in mice and is consistent with improved outcomes in a retrospective human cohort.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L14\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L46\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L30\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The human evidence is explicitly retrospective and non-randomized, so the alignment with better outcomes cannot establish causality for vaccination improving ICI response.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C04\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"strong\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Interferon-associated antigen processing and presentation pathways increase.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L43\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Elimination of benefit with IFNAR1 blockade is a mechanistic control within the tested models; it does not prove the same dependency in all tumour types or in patients.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C05\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The retrospective human comparison is vulnerable to confounding and is not sufficient for direct causal interpretation.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"strong\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"The human analysis is retrospective and non-randomized; residual confounding is likely.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L49\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L51\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Despite these limitations, the analysis may still be hypothesis-generating for prospective trial design rather than definitive evidence of benefit.\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_4iqqeUYW7FHOOnnM0MQpVtLZ\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e095a08508194b48a81f00b1f8e16\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint blockade\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Many cancers do not respond well to immune checkpoint inhibitors (ICIs) because the tumour environment is not inflamed enough and tumour antigens are not presented strongly to the immune system. This study looked at whether delivering an mRNA vaccine directly into tumours can create a local interferon-driven immune activation that helps anti-PD-L1 therapy work better. In mouse tumour models, intratumoral mRNA vaccination was linked to stronger type I interferon signalling, broader antigen display (including a larger MHC-I peptidome), higher PD-L1 expression, and increased intratumoral CD8+ T-cell density. The paper also reports a retrospective analysis of 130 metastatic patients treated with ICIs, where outcomes differed by prior SARS-CoV-2 mRNA vaccination status (reported p=0.01). Because the human data are retrospective and non-randomized, the results should be treated as supportive but not proof that vaccination causes improved ICI benefit; prospective randomized studies are needed before changing clinical protocols.\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"Links intratumoral mRNA vaccination to an interferon-rich tumour state that may enhance immune priming.\\\\\\\",\\\\n    \\\\\\\"Reports broadened antigen presentation after mRNA vaccination, including expansion of the MHC-I peptidome.\\\\\\\",\\\\n    \\\\\\\"Adds a retrospective patient cohort comparison suggesting better survival on ICI among previously vaccinated patients.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human analysis is retrospective and non-randomized, so confounding could explain the association.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing and patient/tumour heterogeneity limit direct causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model results may not translate one-to-one across all human tumours or treatment contexts.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic signals were strongest only in specific model systems rather than uniformly.\\\\\\\" \\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A cancer therapy that blocks inhibitory signals (checkpoints) to help T cells attack tumours, such as drugs targeting PD-1 or PD-L1.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"PD-L1\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A protein that can suppress T-cell activity by engaging PD-1; anti-PD-L1 drugs block this interaction to restore immune attack on tumours.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A family of immune signalling molecules induced during innate sensing of nucleic acids, often triggering antiviral-like inflammation and antigen-presentation pathways.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"MHC-I\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A molecule on cells that displays peptide fragments to CD8+ T cells; expanded MHC-I presentation can make tumours more visible to immune attack.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immunopeptidome\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"The set of peptides presented on MHC molecules in a tissue; measuring it can indicate how many proteins are being shown to the immune system.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"Delivered directly into a tumour (rather than systemically), aiming to trigger local immune changes within the tumour microenvironment.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Do prospective randomized clinical trials confirm that mRNA vaccination strategies improve ICI response rates or survival?\\\\\\\",\\\\n    \\\\\\\"Which tumour types and baseline immune states benefit most from interferon-driven priming and antigen-presentation expansion?\\\\\\\",\\\\n    \\\\\\\"What is the optimal timing and dosing schedule of vaccination relative to starting checkpoint blockade?\\\\\\\",\\\\n    \\\\\\\"Are there safety or tolerability constraints when driving strong interferon responses inside human tumours?\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_82mddRDmlEp89zrM9cH1K9sQ\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine induce an interferon-rich inflammatory state that broadens antigen presentation and thereby sensitizes tumours to anti-PD-L1 immune checkpoint blockade, with supportive evidence in mice and a retrospective human cohort?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice pooled across repeat experiments\",\n      \"description\": \"Preclinical pooled mouse experiments testing intratumoral mRNA vaccine in combination with anti-PD-L1, focused on tumour control and immune changes under combination treatment.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, and vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice pooled across matched controls\",\n      \"description\": \"Matched mouse controls spanning vaccine-only, ICI-only, and vehicle arms used to benchmark whether sensitization requires the combination and to assess null/conditional responses.\"\n    },\n    {\n      \"id\": \"human-metastatic-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 metastatic patients total\",\n      \"description\": \"Retrospective translational cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status for a survival comparison.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used as the exposed group in the survival comparison under ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for outcomes under ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis was retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumour-type mix and treatment-history heterogeneity limits causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumours.\",\n    \"Some mechanistic readouts were strongest in specific models rather than uniform across settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_Kjz3v18ZDjTEf7bFOWETAeW5"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3% comparator\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in the immunopeptidome.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6% comparator\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"Vaccinated subgroup vs unvaccinated subgroup in a retrospective metastatic ICI-treated cohort\",\n      \"interpretation\": \"In the retrospective cohort, prior SARS-CoV-2 mRNA vaccination status correlated with improved survival during ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0 baseline\",\n      \"interpretation\": \"mRNA vaccination in tumours produced a marked induction of a type I interferon response signature.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"After mRNA vaccination, PD-L1 pathway activity increased, potentially increasing targetability for anti-PD-L1 therapy.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"Combination therapy was associated with increased CD8+ T-cell infiltration into tumours.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_ZVcewpaom60Eg2BGx1wsx7Vt"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination induces a type I interferon response in tumours.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"This report summarizes mechanistic induction primarily from tumour measurements and proposed chain; strength may vary by model system.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens antigen presentation, including expansion of the MHC-I peptidome.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"These quantitative peptidome fractions are reported as preclinical readouts and may not directly translate to clinical tumour antigen presentation breadth.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The combined strategy (intratumoral mRNA vaccination plus anti-PD-L1) improves tumour control in mice and is consistent with improved outcomes in a retrospective human cohort.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"The human evidence is explicitly retrospective and non-randomized, so the alignment with better outcomes cannot establish causality for vaccination improving ICI response.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Elimination of benefit with IFNAR1 blockade is a mechanistic control within the tested models; it does not prove the same dependency in all tumour types or in patients.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"The retrospective human comparison is vulnerable to confounding and is not sufficient for direct causal interpretation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        },\n        {\n          \"quote\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n          \"line_ref\": \"L51\"\n        }\n      ],\n      \"caveat\": \"Despite these limitations, the analysis may still be hypothesis-generating for prospective trial design rather than definitive evidence of benefit.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_4iqqeUYW7FHOOnnM0MQpVtLZ"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint blockade\",\n  \"plain_language_summary\": \"Many cancers do not respond well to immune checkpoint inhibitors (ICIs) because the tumour environment is not inflamed enough and tumour antigens are not presented strongly to the immune system. This study looked at whether delivering an mRNA vaccine directly into tumours can create a local interferon-driven immune activation that helps anti-PD-L1 therapy work better. In mouse tumour models, intratumoral mRNA vaccination was linked to stronger type I interferon signalling, broader antigen display (including a larger MHC-I peptidome), higher PD-L1 expression, and increased intratumoral CD8+ T-cell density. The paper also reports a retrospective analysis of 130 metastatic patients treated with ICIs, where outcomes differed by prior SARS-CoV-2 mRNA vaccination status (reported p=0.01). Because the human data are retrospective and non-randomized, the results should be treated as supportive but not proof that vaccination causes improved ICI benefit; prospective randomized studies are needed before changing clinical protocols.\",\n  \"what_is_new\": [\n    \"Links intratumoral mRNA vaccination to an interferon-rich tumour state that may enhance immune priming.\",\n    \"Reports broadened antigen presentation after mRNA vaccination, including expansion of the MHC-I peptidome.\",\n    \"Adds a retrospective patient cohort comparison suggesting better survival on ICI among previously vaccinated patients.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so confounding could explain the association.\",\n    \"Vaccination timing and patient/tumour heterogeneity limit direct causal interpretation.\",\n    \"Mouse model results may not translate one-to-one across all human tumours or treatment contexts.\",\n    \"Some mechanistic signals were strongest only in specific model systems rather than uniformly.\" \n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that blocks inhibitory signals (checkpoints) to help T cells attack tumours, such as drugs targeting PD-1 or PD-L1.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; anti-PD-L1 drugs block this interaction to restore immune attack on tumours.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signalling molecules induced during innate sensing of nucleic acids, often triggering antiviral-like inflammation and antigen-presentation pathways.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cells that displays peptide fragments to CD8+ T cells; expanded MHC-I presentation can make tumours more visible to immune attack.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides presented on MHC molecules in a tissue; measuring it can indicate how many proteins are being shown to the immune system.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Delivered directly into a tumour (rather than systemically), aiming to trigger local immune changes within the tumour microenvironment.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Do prospective randomized clinical trials confirm that mRNA vaccination strategies improve ICI response rates or survival?\",\n    \"Which tumour types and baseline immune states benefit most from interferon-driven priming and antigen-presentation expansion?\",\n    \"What is the optimal timing and dosing schedule of vaccination relative to starting checkpoint blockade?\",\n    \"Are there safety or tolerability constraints when driving strong interferon responses inside human tumours?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_82mddRDmlEp89zrM9cH1K9sQ"
          }
        ],
        "usage": {
          "promptTokens": 6872,
          "cachedTokens": 0,
          "responseTokens": 3620,
          "thinkingTokens": 41,
          "totalTokens": 10533
        },
        "costUsd": 0.06328
      },
      {
        "step": 7,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0cb97140bf27c23b00698e0968e5508194b9df1cdfb49b68f1\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"output\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_hUdttNfYBM4zYzCmI3MmZ23F\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_hUdttNfYBM4zYzCmI3MmZ23F"
          }
        ],
        "usage": {
          "promptTokens": 10607,
          "cachedTokens": 7552,
          "responseTokens": 44,
          "thinkingTokens": 439,
          "totalTokens": 11090
        },
        "costUsd": 0.01342985
      },
      {
        "step": 8,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
        "toolCalls": [],
        "usage": {
          "promptTokens": 11120,
          "cachedTokens": 10880,
          "responseTokens": 59,
          "thinkingTokens": 0,
          "totalTokens": 11179
        },
        "costUsd": 0.0031499999999999996
      }
    ],
    "totalCostUsd": 0.1252818
  }
}
